This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background: Erythropoietin, a hormone produced in the kidney, stimulates bone marrow to produce red blood cells. For over 10 years a recombinant form of erythropoietin, epoetin alfa (EPO), has been used in neonates to treat anemia of prematurity. However, because this treatment often requires daily subcutaneous injections, pain and local skin reactions may occur. In an effort to reduce discomfort caused by these daily injections, an indwelling subcutaneous catheter (Insuflon ) is sometimes used in the neonate. The Insuflon catheter can be inserted into subcutaneous tissue and remain in place for 7 days. To date, no one has published data concerning the clinical utility of the Insuflon catheter for the delivery of EPO in the premature infant. Purpose: To compare safety, efficacy, and nurse satisfaction of the Insuflon catheter with repeated subcutaneous injections of EPO in neonates with anemia of prematurity. Methods: This is a prospective, randomized study. We will measure nurse satisfaction and safety of the Insuflon catheter versus standard injections using a questionnaire provided to the bedside nurse who cares for neonates requiring daily subcutaneous EPO therapy. To measure efficacy, we will document hematocrit and reticulocyte counts for these infants before and after EPO therapy.
Showing the most recent 10 out of 837 publications
